AVIR:NSD-Atea Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 19.22

Change

-0.52 (-2.63)%

Market Cap

USD 1.65B

Volume

0.97M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-2.81 (-1.84%)

USD61.31B 102.33 81.58
VRTX Vertex Pharmaceuticals Incorpo..

+1.67 (+0.79%)

USD55.06B 20.27 14.23
REGN Regeneron Pharmaceuticals, Inc

+10.03 (+1.98%)

USD54.03B 14.44 11.17
BNTX BioNTech SE

-5.34 (-2.87%)

USD47.83B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.34 (+0.78%)

USD38.01B 55.82 39.93
BGNE BeiGene, Ltd

-3.87 (-1.24%)

USD27.16B N/A N/A
SGEN Seagen Inc

-0.06 (-0.04%)

USD26.27B 40.39 34.48
RPRX Royalty Pharma plc

-0.40 (-0.99%)

USD24.64B 22.60 15.13
GMAB Genmab A/S

+0.37 (+1.02%)

USD24.15B 26.59 3.07
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AVIR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.26% 9% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.26% 9% F 5% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 1,148.05% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,148.05% 96% A 97% A+
Average Annual (5 Year Horizon)  
Capital Gain -2.66% 29% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.66% 28% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 39.64% 76% C 45% F
Risk Adjusted Return -6.72% 28% F 20% F
Market Capitalization 1.65B 80% B- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.12 63% D 49% F
Price / Cash Flow Ratio 5.55 10% F 49% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -3.86% 91% A- 48% F
Return on Invested Capital -4.43% 83% B 39% F
Return on Assets -1.56% 91% A- 41% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 11.26 16% F 7% F
Short Percent 5.66% 59% F 37% F
Beta -0.61 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.